Reuters -- Actelion, Europe's largest biotech company, forecast an $80 million hit to 2009 operating profit after an arbitration panel ruled against a unit in a dispute with a Japanese drug firm.
Reuters -- Actelion, Europe's largest biotech company, forecast an $80 million hit to 2009 operating profit after an arbitration panel ruled against a unit in a dispute with a Japanese drug firm.
